Clinical trial
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
NCT00001832 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001832 |
|---|---|
| Title | Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma |
| Official title | Treatment of Patients With Metastatic Melanoma Using Cloned Lymphocytes Following the Administration of a Non-Myeloablative But Lymphocyte Depleting Regimen |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Neoplasm Metastasis |
| Intervention type | Biological, Drug, Procedure |
| Interventions | gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis |
| Enrollment | 170 |
| Start date | Aug 1, 1999 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Nov 4, 1999 |
| Last update posted | Dec 21, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: